This gives the immune cells a clear target to latch onto. That’s not the case for solid tumors, which tend to have many different cell types that often differ within individual tumors.

The researchers highlighted that in low- and middle-income countries, many patients with relapsed (returning) or treatment-resistant B-cell tumors struggle because effective treatments are not widely ...

The results showed that the metastases had significantly lower levels of LAMP2A compared to the primary tumors. Similar patterns ... underlying causes of cancer cell spread.

In addition, there was heavy IgG4 positive plasma cell infiltration associated with storiform fibrosis in the same lesion, probably pointing to a link between ENST-RDD and IgG4-related disorders.

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...

TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor ...

In this review, we summarize TAM ontogeny and polarization, and then explore how TAMs enhance tumor cell migration through the TME, thus facilitating metastasis. We also discuss how chemotherapy and ...

To study the region-dependent cellular diversity within individual GBMs, we performed single-cell RNA sequencing (scRNA-seq) on patient-matched biopsies from the tumor center and the peripheral ...

Objective: The management of giant pituitary tumors is complex, with few publications and recommendations. Consequently, patient’s care mainly relies on clinical experience. We report here a first ...